BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
2.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Xypex 2025 International Best Project Awards - Winners Announced19.3.2026 21:00:00 CET | Press release
Xypex announces 2025 award winners recognizing excellence in concrete durability, engineering performance, and crystalline waterproofing technology. VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / Xypex announces the winners of the 2025 International Best Project Awards, recognizing construction projects that demonstrate excellence in concrete durability, engineering performance, and the use of crystalline waterproofing technology. This year's program received more than 80 project submissions from over 20 countries across five continents, reflecting the global reach of Xypex technology and the strength of its international network of distributors, engineers, contractors, and partners. The submissions represented a broad range of projects across infrastructure, general construction, water and wastewater facilities, industrial structures, and small-scale applications. Projects were evaluated based on engineering complexity, construction challenges, durability requirements, and the int
Brookville DMAX Expansion Highlights the Project Work Behind a Major Ohio Manufacturing Investment19.3.2026 16:00:00 CET | Press release
BROOKVILLE, OH / ACCESS Newswire / March 19, 2026 / General Motors' Duramax Engine Plant (DMAX) expansion in Brookville has become one of the region's most significant industrial projects, tied to a $920 million investment supporting Duramax diesel engine production for GM heavy-duty truck programs, including Chevrolet Silverado HD and GMC Sierra HD models. Public reporting has described the Brookville work as adding about 1.1 million square feet to the existing facility which was previously approximately 250,000 square feet. Notably, the project has created and supported hundreds of local jobs as the site expands its manufacturing footprint in southwest Ohio. This expansion quadruples the current facility size and is designed to create over 800 jobs, supporting high demand for diesel trucks. Among the professionals helping carry that work forward is Sabra Sadeghi, a project architect and engineer who served on the Brookville expansion in an on-site role. The project has been praised f
U.S. Polo Assn. Unveils 2026 Spring-Summer Global Collection, Inspired by Coastal Charleston, South Carolina19.3.2026 12:00:00 CET | Press release
Seasonal and Seaside Styles Debut Alongside U.S. Open Polo Championship Capsule WEST PALM BEACH, FL / ACCESS Newswire / March 19, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has launched its sport-inspired Spring-Summer 2026 Global Collection, a vibrant seasonal lineup inspired by coastal Americana and the relaxed spirit of seaside living. The campaign was photographed in historic Charleston, South Carolina, where Rainbow Row's pastel architecture, coastal landscapes, and the heritage of the Hyde Park Polo Club field create the perfect backdrop for the iconic global brand's latest styles.U.S. Polo Assn. 2026 Spring-Summer Global Collection Photoshoot in Charleston, South Carolina The U.S. Polo Assn. campaign once again highlights the authentic connection between the sport of polo and the globally recognized lifestyle brand inspired by the sport. Apparel and accessories from the Spring-Summer 2026 Global Collection are now available. G
Datavault AI Enters into Definitive Agreement to Acquire NYIAX, Combining AI-Driven Data Monetization with Institutional-Grade Market Infrastructure19.3.2026 11:30:00 CET | Press release
Pending acquisition will integrate NYIAX's blockchain-enabled exchange platform, built on globally recognized financial market technology and jointly owned patents to power next-generation digital marketplaces. PHILADELPHIA, PA / ACCESS Newswire / March 19, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the signing of a Definitive Agreement to acquire NYIAX Inc. ("NYIAX"). The acquisition will bring NYIAX's intellectual property portfolio and blockchain-powered trading platform built on a globally recognized financial market infrastructure platform into Datavault AI's organization. The combined company is expected to make institutional-grade, transparent trading infrastructure available to customers and accelerate the planned commercial launches of specialized exchanges. The transaction builds upon an October 2025 letter of inte
Powerverse and Teltonika Energy Partner to Unlock Intelligent Home Energy & Flexibility19.3.2026 08:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / March 19, 2026 / Powerverse has partnered with Teltonika Energy, part of the Teltonika group, a multinational leader in IoT innovation, to deliver an AI-driven home energy ecosystem that enhances user experience, unlocks flexibility services and drives long-term customer value. Teltonika Energy's hardware is built with reliability, connectivity and performance at its core, and its devices are designed to support the next generation of intelligent home energy systems. "Teltonika Energy is globally recognised for its high-quality, IoT-engineered hardware," said Richard Britton, CEO of Powerverse. "We are thrilled to combine their robust devices with our AI-driven platform to help customers move beyond simple smart control and into active market participation. Together, we are delivering a fully integrated, end-to-end solution that makes it effortless for users to lower costs, reduce their carbon footprint, and unlock the full long-term value of home energy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom